Evidence
Every trial in Nuclide ranked by a disclosed evidence-strength score, with its primary endpoint drawn as people out of 100 or as median months. The score measures how much and what kind of evidence exists, not how large the benefit is.
How the score is computed
- Phase: 3 → 30 · 2/3 → 22 · 2 → 15 · 1/2 → 8 · 1 → 4 · observational or platform → 10
- Size: 5 × log10(enrolled), capped at 20 (100 people → 10, 1,000 → 15, 10,000 → 20)
- Primary endpoint: overall survival → 20 · time to progression or recurrence → 14 · surrogate (response, pCR, detection) → 8
- Result: positive → 15 · mixed → 6 · ongoing → 0 · negative or withdrawn → −20
- Replication: an independent or consistent confirming study → 10
- A linked product is approved → 5
Products score from their status tier, their best linked trial, and approvals; technologies and targets from their status and best linked product. Full code in src/lib/evidence.ts.
Primary endpoints as pictures
VISION · PSMA+ metastatic castration-resistant prostate cancer after ARPI and taxane
CHAARTED (E3805) · Metastatic hormone-sensitive prostate cancer
IELSG37 · Primary mediastinal large B-cell lymphoma in complete metabolic response on PET after rituximab-based immunochemotherapy
Progression-free survival at 30 monthsprimary
Observation96.7 of 100
n = 132
Consolidation radiotherapy 30 Gy98.5 of 100
n = 136
Download
PSMAfore · PSMA+ mCRPC after one ARPI, taxane-naive
ALSYMPCA · Symptomatic bone-metastatic CRPC without visceral disease
RATHL · Advanced Hodgkin lymphoma
Progression-free survival at 3 years (PET2-negative)primary
ABVD85.7 of 100
n = 470
AVD84.4 of 100
n = 465
Download
DECISION · Radioiodine-refractory differentiated thyroid cancer
SELECT · Radioiodine-refractory differentiated thyroid cancer with progression
PROSPER · Non-metastatic castration-resistant prostate cancer with a PSA doubling time of ten months or less
STAMPEDE · Multi-arm multi-stage platform in men starting long-term hormone therapy for high-risk locally advanced or metastatic prostate cancer
EMBARK · High-risk biochemical recurrence (PSA doubling time ≤9 months) after local therapy
Metastasis-free survival, enzalutamide + leuprolide vs leuprolideprimary
HR 0.42 (0.3 to 0.61) · p <0.001
Enzalutamide + leuprolide, 5-year MFS87.3 of 100
n = 355
Leuprolide alone, 5-year MFS71.4 of 100
n = 358
Download
RADIANT-3 and RADIANT-4 · Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302)
All trials by evidence strength
| # | Trial | Phase | Result | Primary endpoint | Enrolled | Score |
|---|---|---|---|---|---|---|
| 1 | VISION PSMA+ metastatic castration-resistant prostate cancer after ARPI and taxane: 177Lu-PSMA-617 + SOC vs SOC | Phase 3 | Positive | Overall survival: 15.3 months vs 11.3 months, HR 0.62 | 861 | 95 Strong |
| 2 | CHAARTED (E3805) Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT | Phase 3 | Positive | Overall survival: 57.6 months vs 44 months, HR 0.61 | 790 | 94 Strong |
| 3 | PSMAddition PSMA-positive metastatic hormone-sensitive prostate cancer: 177Lu-PSMA-617 + ADT + ARPI vs ADT + ARPI | Phase 3 | Positive | Radiographic progression-free survival: Updated HR 0.67; OS HR 0.80, immature | 1,144 | 89 Strong |
| 4 | IELSG37 Primary mediastinal large B-cell lymphoma in complete metabolic response on PET after rituximab-based immunochemotherapy: consolidation mediastinal radiotherapy versus observation | Phase 3 | Positive | Progression-free survival at 30 months: 96.7% vs 98.5% | 545 | 88 Strong |
| 5 | PSMAfore PSMA+ mCRPC after one ARPI, taxane-naive: 177Lu-PSMA-617 vs ARPI switch | Phase 3 | Positive | Radiographic progression-free survival: 12 months vs 5.6 months, HR 0.41 | 469 | 87 Strong |
| 6 | ALSYMPCA Symptomatic bone-metastatic CRPC without visceral disease: radium-223 vs placebo | Phase 3 | Positive | Overall survival: 14.9 months vs 11.3 months, HR 0.7 | 921 | 85 Strong |
| 7 | RATHL Advanced Hodgkin lymphoma: interim-PET-guided omission of bleomycin (AVD) vs continued ABVD | Phase 3 | Positive | Progression-free survival at 3 years (PET2-negative): 85.7% vs 84.4% | 1,214 | 84 Strong |
| 8 | DECISION Radioiodine-refractory differentiated thyroid cancer: sorafenib vs placebo | Phase 3 | Positive | Progression-free survival: 10.8 months vs 5.8 months, HR 0.59 | 417 | 82 Strong |
| 9 | ECLIPSE PSMA-positive mCRPC after ARPI, taxane-naive: 177Lu-PSMA-I&T (7.4 GBq × 6) vs ARPI switch | Phase 3 | Positive | Radiographic progression-free survival: Met per sponsor; medians pending publication | 439 | 82 Strong |
| 10 | SELECT Radioiodine-refractory differentiated thyroid cancer with progression: lenvatinib vs placebo | Phase 3 | Positive | Progression-free survival: 18.3 months vs 3.6 months, HR 0.21 | 392 | 82 Strong |
| 11 | PROSPER Non-metastatic castration-resistant prostate cancer with a PSA doubling time of ten months or less: enzalutamide against placebo, both with continued androgen deprivation | Phase 3 | Positive | Metastasis-free survival: 36.6 months vs 14.7 months, HR 0.29 | 1,401 | 80 Strong |
| 12 | STAMPEDE Multi-arm multi-stage platform in men starting long-term hormone therapy for high-risk locally advanced or metastatic prostate cancer: docetaxel, zoledronic acid, celecoxib, abiraterone, radiotherapy to the prostate, abiraterone with enzalutamide, metformin and transdermal oestradiol added to ADT and compared with ADT alone | Platform trial | Positive | Overall survival, abiraterone arm (M1 subgroup): 6-year OS 60% · 6-year OS 45% | 11,992 | 80 Strong |
| 13 | EMBARK High-risk biochemical recurrence (PSA doubling time ≤9 months) after local therapy: enzalutamide + leuprolide, enzalutamide alone, or leuprolide alone | Phase 3 | Positive | Metastasis-free survival, enzalutamide + leuprolide vs leuprolide: 87.3% vs 71.4%, HR 0.42 | 1,068 | 79 Strong |
| 14 | RADIANT-3 and RADIANT-4 Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302): everolimus vs placebo | Phase 3 | Positive | Progression-free survival (RADIANT-3): 11 months vs 4.6 months, HR 0.35 | 712 | 78 Strong |
| 15 | COMPETE Progressive grade 1-2 SSTR-positive GEP-NETs: 177Lu-edotreotide vs everolimus | Phase 3 | Positive | Progression-free survival: 23.9 months vs 14.1 months, HR 0.67 | 324 | 77 Strong |
| 16 | ESTIMABL2 Low-risk differentiated thyroid cancer (pT1a-T1b N0/Nx) after total thyroidectomy: no radioiodine vs 1.1 GBq ablation | Phase 3 | Positive | Patients without events at 3 years: 95.6% vs 95.9% | 776 | 77 Strong |
| 17 | CABINET (Alliance A021602) Previously treated advanced pancreatic (n=95) and extra-pancreatic (n=203) NETs: cabozantinib vs placebo | Phase 3 | Positive | Progression-free survival (pancreatic NET): 13.8 months vs 4.4 months, HR 0.23 | 298 | 76 Strong |
| 18 | HiLo Differentiated thyroid cancer needing ablation: low-dose (1.1 GBq) vs high-dose (3.7 GBq) radioiodine, with recombinant TSH or thyroid hormone withdrawal | Phase 3 | Positive | Successful ablation: 85% vs 88.9% | 438 | 76 Strong |
| 19 | NETTER-1 Inoperable, progressive midgut neuroendocrine tumours: 177Lu-Dotatate plus octreotide versus high-dose octreotide LAR | Phase 3 | Positive | Progression-free survival at 20 months: 65.2% vs 10.8%, HR 0.21 | 231 | 76 Strong |
| 20 | GHSG HD21 Untreated advanced-stage classical Hodgkin lymphoma, age 18-60: PET-guided BrECADD vs escalated BEACOPP | Phase 3 | Positive | Progression-free survival at 4 years: 94.3% vs 90.9%, HR 0.66 | 1,500 | 75 Strong |
| 21 | IoN Low-risk differentiated thyroid cancer (pT1-T2, N0/Nx, no adverse features) after thyroidectomy: no radioiodine vs radioiodine ablation | Phase 2/3 | Positive | Recurrence-free at 5 years: 98% vs 96% | 504 | 75 Strong |
| 22 | proPSMA High-risk localised prostate cancer staging: PSMA PET/CT vs CT + bone scan | Phase 3 | Positive | Accuracy for pelvic nodal or distant metastases (AUC): 92% vs 65% | 302 | 75 Strong |
| 23 | SPLASH PSMA-positive mCRPC after one ARPI, taxane-naive: 177Lu-PNT2002 vs ARPI switch | Phase 3 | Mixed | Radiographic progression-free survival: 9.5 months vs 6 months, HR 0.71 | 455 | 73 Solid |
| 24 | PHERGain HER2+ early breast cancer: chemotherapy-free trastuzumab + pertuzumab with early 18F-FDG PET response assessment to decide whether chemotherapy is needed | Phase 2 | Positive | 3-year invasive disease-free survival (PET-adapted arm): 95.4% | 377 | 67 Solid |
| 25 | POP-RT High-risk node-negative prostate cancer: prostate-only versus whole-pelvic radiotherapy, both with hormone therapy | Phase 3 | Positive | Biochemical failure-free survival at 5 years: 95% vs 81.2% | 224 | 65 Solid |
| 26 | TheraP (ANZUP 1603) mCRPC after docetaxel: 177Lu-PSMA-617 vs cabazitaxel, PSMA PET/FDG PET selected | Phase 2 | Positive | PSA response ≥50%: 66% vs 37% | 201 | 65 Solid |
| 27 | AURORA Adults with suspected coronary artery disease undergoing myocardial perfusion imaging before invasive coronary angiography; a diagnostic (cardiac imaging) trial | Phase 3 | Completed | Sensitivity for coronary artery disease (≥50% stenosis by quantitative coronary angiography): 80.3% vs 68.7% | 730 | 52 Solid |
| 28 | LIGHTHOUSE Men with newly diagnosed, treatment-naive unfavourable intermediate- to very-high-risk prostate cancer planned for radical prostatectomy with pelvic lymph node dissection; a staging (diagnostic) trial | Phase 3 | Completed | Sensitivity for pelvic lymph node metastases vs histopathology at prostatectomy: 27% | 356 | 51 Solid |
| 29 | SPOTLIGHT Men with biochemical recurrence of prostate cancer after prior curative-intent treatment, being considered for salvage therapy; a diagnostic (imaging) trial | Phase 3 | Completed | Verified detection rate vs composite standard of truth (histopathology or confirmatory imaging): 52% | 391 | 51 Solid |
| 30 | CONDOR Men with biochemically recurrent prostate cancer after radical prostatectomy or radiotherapy, with negative or equivocal conventional imaging; a diagnostic (imaging) trial | Phase 3 | Completed | Correct localisation rate vs composite standard of truth: 86% | 208 | 50 Solid |
| 31 | ZIRCON Adults with a single indeterminate renal mass (cT1, up to 7 cm) suspicious for clear cell renal cell carcinoma, scheduled for nephrectomy; a diagnostic (imaging) trial, not a treatment line | Phase 3 | Completed | Sensitivity for ccRCC detection vs surgical histopathology: 85.5% | 300 | 50 Solid |
| 32 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | Phase 3 | Recruiting | - | 670 | 49 Emerging |
| 33 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment | Phase 3 | Recruiting | - | 520 | 49 Emerging |
| 34 | ACTION-1 SSTR-positive GEP-NETs progressing after 177Lu somatostatin-analogue therapy: 225Ac-DOTATATE (RYZ101) vs investigator's choice | Phase 3 | Active | - | 343 | 48 Emerging |
| 35 | Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups | Phase 3 | Active | - | 398 | 48 Emerging |
| 36 | FALCON Men with a first episode of biochemical recurrence of prostate cancer after curative-intent primary therapy, being considered for salvage therapy; a diagnostic (management-impact) trial | Phase 3 | Completed | Proportion of patients with a revised management plan (pre-scan vs post-scan): 64% | 104 | 48 Emerging |
| 37 | PSMA PET Combined With MRI for the Detection of PCa A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa). | Phase 3 | Recruiting | - | 338 | 48 Emerging |
| 38 | CYC-009: Technegas versus xenon-133 ventilation imaging Adults referred for ventilation scintigraphy, imaged with both Technegas and xenon-133 by planar technique, to test whether Technegas is non-inferior to xenon-133 for the distribution of pulmonary ventilation. This is the registration study behind the 2023 US approval; ClinicalTrials.gov records its status as terminated with 226 participants actually enrolled. | Phase 3 | Historic | - | 226 | 47 Emerging |
| 39 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin | Phase 3 | Active | - | 259 | 47 Emerging |
| 40 | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | Phase 3 | Active | - | 226 | 47 Emerging |
| 41 | [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer | Phase 3 | Active | - | 138 | 46 Emerging |
| 42 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | Phase 3 | Active | - | 187 | 46 Emerging |
| 43 | Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | Phase 3 | Completed | - | 131 | 46 Emerging |
| 44 | A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | - | 1,203 | 45 Emerging |
| 45 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | - | 940 | 45 Emerging |
| 46 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort | Phase 3 | Active | - | 691 | 44 Emerging |
| 47 | A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer A Phase III, Randomized, Open-Label, Multicenter Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Recruiting | - | 370 | 43 Emerging |
| 48 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) | Phase 3 | Recruiting | - | 450 | 43 Emerging |
| 49 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection | Phase 3 | Active | - | 439 | 43 Emerging |
| 50 | Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer | Phase 3 | Recruiting | - | 380 | 43 Emerging |
| 51 | Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | Phase 3 | Recruiting | - | 365 | 43 Emerging |
| 52 | OSPREY Cohort A: men with high-risk prostate cancer planned for radical prostatectomy with lymphadenectomy (initial staging). Cohort B: men with suspected recurrent or metastatic prostate cancer feasible for biopsy | Phase 2/3 | Completed | Specificity for pelvic nodal disease, Cohort A, vs histopathology at prostatectomy: 97.9% | 385 | 43 Emerging |
| 53 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | Phase 3 | Recruiting | - | 220 | 42 Emerging |
| 54 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC A Randomized, Multicenter, Phase III Open-label Study: Efficacy and Safety of Comparing SAF-189s With Crizotinib in First-line Anaplastic Lymphoma Kinase-positive Advanced and Metastatic NSCLC | Phase 3 | Active | - | 275 | 42 Emerging |
| 55 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) | Phase 3 | Recruiting | - | 240 | 42 Emerging |
| 56 | This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Safety of 68Ga-NYM032 Injection PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer | Phase 3 | Recruiting | - | 232 | 42 Emerging |
| 57 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer | Phase 3 | Recruiting | - | 200 | 42 Emerging |
| 58 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours | Phase 3 | Active | - | 196 | 41 Emerging |
| 59 | A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy | Phase 3 | Recruiting | - | 144 | 41 Emerging |
| 60 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 3 | Active | - | 153 | 41 Emerging |
| 61 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study A Confirmatory, Open-label, Single-arm, Multi-centre Study to Evaluate Safety, Tolerability and Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) to Non-invasively Detect Clear Cell Renal Cell Carcinoma (ccRCC) by Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Chinese Patients With Indeterminate Renal Masses (ZIRCON-CP Study) | Phase 3 | Recruiting | - | 82 | 40 Emerging |
| 62 | ASTRA High-risk differentiated thyroid cancer: selumetinib + adjuvant radioiodine vs placebo + radioiodine | Phase 3 | Negative | Complete remission at 18 months: 40% vs 38.5% | 233 | 40 Emerging |
| 63 | ENZA-p Metastatic castration-resistant prostate cancer, PSMA-PET-positive, no prior docetaxel or ARPI for mCRPC, with at least two risk factors for early progression on enzalutamide; first-line mCRPC | Phase 2 | Active | PSA progression-free survival: 13 months vs 7.8 months, HR 0.43 | 162 | 40 Emerging |
| 64 | ALPHAMEDIX-02 Unresectable or metastatic SSTR-positive GEP-NETs, PRRT-naive and PRRT-exposed cohorts: 212Pb-DOTAMTATE single arm | Phase 2 | Positive | Objective response rate (PRRT-naive): 54.3% | - | 38 Emerging |
| 65 | IDEAS (Imaging Dementia-Evidence for Amyloid Scanning) Medicare beneficiaries with mild cognitive impairment or dementia of uncertain cause, evaluated by dementia specialists; a coverage-with-evidence-development registry study, not a treatment trial | Observational study | Completed | Change in composite patient management plan within 90 days, mild cognitive impairment group: 60.2% | 18,488 | 38 Emerging |
| 66 | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma | Phase 3 | Active | - | 43 | 38 Emerging |
| 67 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 3 | Recruiting | - | 40 | 38 Emerging |
| 68 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Phase 2/3 | Recruiting | - | 443 | 35 Emerging |
| 69 | SARAH and SIRveNIB Locally advanced HCC: yttrium-90 radioembolisation vs sorafenib | Phase 3 | Negative | Overall survival (SARAH): 8 months vs 9.9 months, HR 1.15 | - | 35 Emerging |
| 70 | PSMA-PET to Guide Prostatectomy PSMA-PET to Guide Prostatectomy: A Randomized Trial | Phase 2/3 | Recruiting | - | 288 | 34 Emerging |
| 71 | UpFrontPSMA De novo, high-volume metastatic hormone-sensitive prostate cancer, first-line, given within 12 weeks of diagnosis and no more than 4 weeks of androgen deprivation therapy | Phase 2 | Active | Undetectable PSA (≤0.2 ng/mL) at 48 weeks: 41% vs 16% | 130 | 34 Emerging |
| 72 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | Phase 2/3 | Recruiting | - | 175 | 33 Emerging |
| 73 | A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Somatostatin Receptor Positive Neuroendocrine Neoplasms | Phase 2/3 | Recruiting | - | 85 | 32 Emerging |
| 74 | AHOD2131 (COG / NCTN) Newly diagnosed stage I-II classical Hodgkin lymphoma, age 5-60: standard therapy vs brentuximab vedotin + nivolumab (response-adapted), with or without radiation | Phase 3 | Recruiting | - | - | 30 Emerging |
| 75 | COG ANBL1531 Newly diagnosed high-risk neuroblastoma: 131I-MIBG added to induction (randomised, MIBG-avid); lorlatinib added for ALK-aberrant tumours (non-randomised arm) | Phase 3 | Active | - | - | 30 Emerging |
| 76 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active | - | 85 | 30 Emerging |
| 77 | TheraSphere With Durvalumab and Tremelimumab for HCC An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC) | Phase 2 | Active | - | 100 | 30 Emerging |
| 78 | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy | Phase 2 | Active | - | 58 | 29 Preliminary |
| 79 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function. | Phase 2 | Active | - | 23 | 27 Preliminary |
| 80 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active | - | 138 | 26 Preliminary |
| 81 | Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer. | Phase 2 | Recruiting | - | 168 | 26 Preliminary |
| 82 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Phase 2 | Recruiting | - | 114 | 25 Preliminary |
| 83 | A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) A Phase Ⅱ Randomized, Parallel-group, Open-label, Active-controlled Trial to Assess the Efficacy, Safety and Pharmacokinetics of the Long-acting Octreotide Subcutaneous Injection (SYHX2008) Versus Octreotide Microspheres (Sandostatin LAR@) in Patients With GEP-NET | Phase 2 | Recruiting | - | 90 | 25 Preliminary |
| 84 | AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617) PSMA-positive mCRPC: actinium-225 PSMA radioligands vs standard of care, including after 177Lu-PSMA | Phase 2 | Active | - | 110 | 25 Preliminary |
| 85 | Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | - | 93 | 25 Preliminary |
| 86 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM) | Phase 2 | Active | - | 120 | 25 Preliminary |
| 87 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) | Phase 2 | Active | - | 11 | 25 Preliminary |
| 88 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial. | Phase 2 | Active | - | 115 | 25 Preliminary |
| 89 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Phase 2 | Recruiting | - | 71 | 24 Preliminary |
| 90 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Active | - | 63 | 24 Preliminary |
| 91 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC A Phase II, Open-label, Multi-Center, Randomized Study of Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active | - | 7 | 24 Preliminary |
| 92 | HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Positron Emission Tomography and Computed Tomography (PET/CT) With 68Ga-ABS011 in Metastatic Breast Cancer (mBC) and Other Metastatic Solid Carcinomas. | Phase 2 | Recruiting | - | 60 | 24 Preliminary |
| 93 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition | Phase 1/2 | Active | - | 148 | 24 Preliminary |
| 94 | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer | Phase 1/2 | Recruiting | - | 152 | 24 Preliminary |
| 95 | PRINCE Metastatic castration-resistant prostate cancer with high PSMA expression, after prior androgen receptor pathway inhibitor (with prior docetaxel allowed); combination therapy trial | Phase 1/2 | Completed | PSA50 response rate (co-primary with safety): 76% | 37 | 24 Preliminary |
| 96 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy | Phase 2 | Recruiting | - | 60 | 24 Preliminary |
| 97 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Recruiting | - | 123 | 23 Preliminary |
| 98 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer | Phase 2 | Active | - | 49 | 23 Preliminary |
| 99 | Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer A Phase 2, Open-Label, Multicenter Study to Investigate the Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Lung Cancer Resection | Phase 2 | Recruiting | - | 35 | 23 Preliminary |
| 100 | LuTectomy Men with high-risk localised prostate cancer and high PSMA uptake, scheduled for radical prostatectomy; neoadjuvant, pre-surgical setting | Phase 1/2 | Active | Highest tumour radiation absorbed dose after cycle 1: 35.5 Gy | 20 | 23 Preliminary |
| 101 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase | Phase 1/2 | Active | - | 55 | 22 Preliminary |
| 102 | Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy | Phase 2 | Recruiting | - | 20 | 22 Preliminary |
| 103 | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants With Suspected Recurrent Brain Metastases From Solid Tumors | Phase 2 | Active | - | 30 | 22 Preliminary |
| 104 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC) | Phase 1/2 | Recruiting | - | 590 | 22 Preliminary |
| 105 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | Phase 1/2 | Recruiting | - | 345 | 21 Preliminary |
| 106 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Phase 1/2 | Active | - | 20 | 20 Preliminary |
| 107 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor | Phase 1/2 | Recruiting | - | 222 | 20 Preliminary |
| 108 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Recruiting | - | 270 | 20 Preliminary |
| 109 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | Active | - | 211 | 20 Preliminary |
| 110 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Finding and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma | Phase 1/2 | Recruiting | - | 300 | 20 Preliminary |
| 111 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors | Phase 1/2 | Recruiting | - | 300 | 20 Preliminary |
| 112 | Test-retest Evaluation of [18F]F-AraG PET Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients | Phase 2 | Recruiting | - | 10 | 20 Preliminary |
| 113 | A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer | Phase 1/2 | Recruiting | - | 180 | 19 Preliminary |
| 114 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors | Phase 1/2 | Recruiting | - | 150 | 19 Preliminary |
| 115 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Phase 1/2 | Recruiting | - | 138 | 19 Preliminary |
| 116 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer Ph I/IIa Escalation/Expansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive/Treatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors | Phase 1/2 | Recruiting | - | 90 | 18 Preliminary |
| 117 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | Phase 1/2 | Active | - | 91 | 18 Preliminary |
| 118 | A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-Cancer Agents in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Recruiting | - | 85 | 18 Preliminary |
| 119 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1/2 | Recruiting | - | 90 | 18 Preliminary |
| 120 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors | Phase 1/2 | Recruiting | - | 84 | 18 Preliminary |
| 121 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer | Phase 1/2 | Recruiting | - | 82 | 18 Preliminary |
| 122 | Lead-212 PSV359 Therapy for Patients With Solid Tumors A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive | Phase 1/2 | Recruiting | - | 112 | 18 Preliminary |
| 123 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | Phase 1/2 | Recruiting | - | 90 | 18 Preliminary |
| 124 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications A Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Phase 1/2 | Recruiting | - | 71 | 17 Preliminary |
| 125 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Phase 1/2 | Recruiting | - | 61 | 17 Preliminary |
| 126 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer | Phase 1/2 | Recruiting | - | 54 | 17 Preliminary |
| 127 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants With Castration-Resistant Prostate Cancer (CRPC) | Phase 1/2 | Recruiting | - | 73 | 17 Preliminary |
| 128 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment | Phase 1/2 | Active | - | 60 | 17 Preliminary |
| 129 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, -Radiation Dosimetry, and Preliminary Anti-Neoplastic Activity of LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma | Phase 1/2 | Recruiting | - | 55 | 17 Preliminary |
| 130 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors A Phase I/II Clinical Study to Evaluate the Safety, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Efficacy of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | Phase 1/2 | Recruiting | - | 48 | 16 Preliminary |
| 131 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial) | Phase 1/2 | Recruiting | - | 26 | 15 Preliminary |
| 132 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | Phase 1/2 | Active | - | 30 | 15 Preliminary |
| 133 | A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | Phase 1/2 | Recruiting | - | 30 | 15 Preliminary |
| 134 | Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients With Malignant Cutaneous Lesions From Advanced Solid Tumors | Phase 1/2 | Recruiting | - | 18 | 14 Preliminary |
| 135 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1). | Phase 1/2 | Active | - | 16 | 14 Preliminary |
| 136 | A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | Phase 1/2 | Recruiting | - | 10 | 13 Preliminary |